Study IDs Risk Factors for Extraintestinal Manifestations of IBD
By Lori Solomon HealthDay Reporter
WEDNESDAY, April 17, 2024 -- Certain demographic, clinical, and genetic factors heighten the risk for extraintestinal manifestations (EIMs) with inflammatory bowel disease (IBD), according to a study published online March 13 in Gastroenterology.
Michelle Khrom, from Cedars-Sinai Medical Center in Los Angeles, and colleagues investigated the clinical, serologic, and genetic factors associated with EIM complications in IBD. The analysis included 12,083 unrelated individuals with IBD and European ancestry with presence or absence of EIMs (e.g., ankylosing spondylitis, primary sclerosing cholangitis [PSC], peripheral arthritis, and skin and ocular manifestations) across four cohorts.
The researchers found that most EIMs occurred more commonly in women, in those with Crohn disease (especially colonic disease location), and in those who required surgery (both Crohn disease and ulcerative colitis). Risk for EIMs, except for PSC, was higher with smoking. Serologic associations were seen for PSC (immunoglobulin [Ig]G and IgA, perinuclear antinuclear cytoplasmic antibody; anti-Saccharomyces cerevisiae antibodies; and antiflagellin) and any EIM (IgG and IgA, perinuclear antinuclear cytoplasmic antibody; anti-Saccharomyces cerevisiae antibodies; and anti-Pseudomonas fluorescens-associated sequence). Significant genome-wide associations were seen within major histocompatibility complex and CPEB4.
"These inflammatory manifestations outside the gut impact about 40 percent of our patients with IBD," coauthor Dermot McGovern, M.D., Ph.D., also from Cedars-Sinai, said in a statement. "Our findings will help us identify those at risk of developing these related conditions."
One author disclosed ties to Merck, Prometheus Biosciences (acquired by Merck), Takeda, and Prometheus Labs.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
People With Inflammatory Bowel Disease Face Barriers to Health Care
MONDAY, Oct. 21, 2024 -- Patients with inflammatory bowel disease (IBD) continue to experience barriers to health care access and treatment and financial struggles, according to a...
Researchers Find Biomarker Tied to Severity of Ulcerative Colitis
FRIDAY, Oct. 18, 2024 -- For patients with ulcerative colitis, the HLA-DRB1*01:03 allele is associated with severe ulcerative colitis, according to a research letter published...
Anti-TL1A Monoclonal Antibody, Tulisokibart, Aids Ulcerative Colitis
FRIDAY, Oct. 4, 2024 -- Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.